Zymeworks appoints Ciongoli and Landry to board; Cox resigns; private placement of $4.99M to Ciongoli

Zymeworks Inc.

Gregory Ciongoli and Robert E. Landry appointed as directors effective Aug 10, 2025; Ciongoli as Class II, Landry as Class I; both join Audit Committee.
Troy M. Cox resigned from Board and Audit Committee effective Aug 9, 2025; no disagreement with company.
Company sold 415,000 shares to Ciongoli at $12.02/share for aggregate $4,988,300 in unregistered private placement.
Proceeds from private placement will be used for working capital and general corporate purposes; closing expected Aug 12, 2025.
Press release highlights upcoming Q4 2025 data readout for HERIZON-GEA-01 and recent zanidatamab approvals in US, Europe, and China.

item 1.01 item 5.02 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.